M&A / Deals BioMarin acquires Amicus Therapeutics for $4.8bn Pharmaceutical TechnologyBioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.Rare DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal. Rare Disease Read full story Post navigation Previous: FDA approves AstraZeneca’s Saphnelo for SLENext: Boehringer/Zealand dual-acting drug causes 16.6% weight loss Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
